Animal Models and Cell Lines

>Single Humanized Immune-Checkpoint Mice
B-hCD47 (B/c) mice
CD47 is an important “self ” mark on the cell surface and inhibits macrophagocytosis by interaction with SIRPα on macrophage surface. Animal studies have shown that a CD47 antibody is an effective treatment for multiple types of tumors. CD47 is another target for tumor immunity following PD-1/PD-L1.
B-hCD47 mice
CD47 is an important “self” mark on the cell surface and inhibits macrophage mediated phagocytosis by the interaction with SIRPA expressed on the surface of macrophages. Animal studies have demonstrated that targeting CD47 with antibodies is a promising approach for the treatment of multiple tumor types.
B-CTLA4 mice
The inhibition of CTLA4 by its inhibitory antibodies enhances T cell activity. The CTLA4 antibody is the first FDA-approved antibody to treat advanced melanoma.
B-hTNFRSF18(GITR) mice
As a co-stimulatory signal of T cells, TNFRSF18 is up-regulated upon the activation of T cells, and in turn promotes T cell proliferation. CD25+/CD4+ regulatory T cells are known to mediate immune tolerance, and GITR agonist antibodies can reverse this immune tolerance, and show anti-tumor effects in multiple tumor models.
B-hLAG3 mice
The expression of LAG3 is associated with the negative immunoregulatory function of specific T cells. Inhibition of LAG3 function enhances the anti-tumor effect of specific CD8+ T cells, therefore LAG3 is a potential target for tumor immunotherapy.
B-hTNFRSF4(OX40) mice
The coactivation of OX40/OX40L enhances T cell function, including cytokine production, proliferation and T cell survival. An OX40 agonist can reduce Regulatory T cells (Tregs) and improve anti-tumor activity.
© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud